In Bio-Rad Labs., Inc. v. ITC, a Federal Circuit panel affirmed the U.S. International Trade Commission’s (ITC) finding that Bio-Rad infringed patents, directed to gene sequencing technology, owned by 10X Genomics Inc. In affirming the ITC, the panel, inter alia, rejected Bio-Rad’s defense that it co-owned the asserted patents based on assignment provisions that two named inventors signed while employees of Bio-Rad and its predecessor, QuantaLife, even though the claimed inventions were not made until…